Impact of donor and recipient single nucleotide polymorphisms of IL28B rs8099917 in living donor liver transplantation for hepatitis C

Nobuhiro Harada; Sumihito Tamura; Yasuhiko Sugawara; Junichi Togashi; Takeaki Ishizawa; Junichi Kaneko; Taku Aoki; Yoshihiro Sakamoto; Kiyoshi Hasegawa; Tomohiro Tanaka; Noriyo Yamashiki; Norihiro Kokudo

doi:10.1371/journal.pone.0090462

Back

Impact of donor and recipient single nucleotide polymorphisms of IL28B rs8099917 in living donor liver transplantation for hepatitis C

Journal article

Open access

Peer reviewed

Impact of donor and recipient single nucleotide polymorphisms of IL28B rs8099917 in living donor liver transplantation for hepatitis C

Nobuhiro Harada, Sumihito Tamura, Yasuhiko Sugawara, Junichi Togashi, Takeaki Ishizawa, Junichi Kaneko, Taku Aoki, Yoshihiro Sakamoto, Kiyoshi Hasegawa, Tomohiro Tanaka, …

PloS one, Vol.9(3), pp.e90462-e90462

2014

DOI: 10.1371/journal.pone.0090462

PMCID: PMC3944011

PMID: 24599320

Files and links (1)

url

https://doi.org/10.1371/journal.pone.0090462View

Published (Version of record) Open Access

Abstract

Single nucleotide polymorphisms of interleukin-28B (IL28B) rs8099917 are reported to be associated with virologic clearance in interferon-and ribavirin -based treatment for hepatitis C virus (HCV)-infected patients. We examined virologic response in accordance with IL28B polymorphisms in our living donor liver transplantation series under a preemptive interferon and RBV treatment approach. Adequate DNA samples from both the recipient and donor for the study of single nucleotide polymorphisms of IL28B were available from 96 cases and were the subjects of the present study. Various clinical factors related with virologic response including early virologic response (EVR) and sustained virologic response (SVR) were examined. Totally 51% presented with EVR and 44% achieved SVR. Presence of the major allele (TT) in either the recipient or the donor corresponded to SVR of 53% and 48%. Presence of the minor allele (TG or GG) corresponded to SVR of 26% and 32%. Multivariate analysis revealed that genotype of HCV or EVR, but not IL28B polymorphisms in either the recipient or donor, was an independent factor for achieving SVR. When virologic response to treatment was incorporated into analysis, the impact of IL28B polymorphism on virological clearance remained relative to other factors and was not significantly independent.

Recombinant Proteins - therapeutic use

Interferon-alpha - pharmacology

Liver Transplantation

Humans

Middle Aged

Hepacivirus - genetics

Living Donors

Young Adult

Interleukins - genetics

Adult

Retrospective Studies

Drug Therapy, Combination

Antiviral Agents - pharmacology

Genetic Association Studies

Antiviral Agents - therapeutic use

Ribavirin - therapeutic use

Interferon-alpha - therapeutic use

Hepatitis C, Chronic - surgery

Genotype

Treatment Outcome

Recombinant Proteins - pharmacology

Hepatitis C, Chronic - drug therapy

Sequence Analysis, DNA

Adolescent

Interferon alpha-2

Aged

Polymorphism, Single Nucleotide

Hepatitis C, Chronic - genetics

Ribavirin - pharmacology

Details

Title: Subtitle: Impact of donor and recipient single nucleotide polymorphisms of IL28B rs8099917 in living donor liver transplantation for hepatitis C
Creators: Nobuhiro Harada - Division of Artificial Organ and Transplantation, The University of Tokyo Hospital, Tokyo, Japan
Sumihito Tamura - Division of Artificial Organ and Transplantation, The University of Tokyo Hospital, Tokyo, Japan
Yasuhiko Sugawara - Division of Artificial Organ and Transplantation, The University of Tokyo Hospital, Tokyo, Japan; Organ Transplantation Service, The University of Tokyo Hospital, Tokyo, Japan
Junichi Togashi - Division of Artificial Organ and Transplantation, The University of Tokyo Hospital, Tokyo, Japan
Takeaki Ishizawa - Division of Hepato-Biliary and Pancreatic Surgery, Department of Surgery, The University of Tokyo Hospital, Tokyo, Japan
Junichi Kaneko - Division of Artificial Organ and Transplantation, The University of Tokyo Hospital, Tokyo, Japan
Taku Aoki - Division of Hepato-Biliary and Pancreatic Surgery, Department of Surgery, The University of Tokyo Hospital, Tokyo, Japan
Yoshihiro Sakamoto - Division of Hepato-Biliary and Pancreatic Surgery, Department of Surgery, The University of Tokyo Hospital, Tokyo, Japan
Kiyoshi Hasegawa - Division of Hepato-Biliary and Pancreatic Surgery, Department of Surgery, The University of Tokyo Hospital, Tokyo, Japan
Tomohiro Tanaka - Organ Transplantation Service, The University of Tokyo Hospital, Tokyo, Japan
Noriyo Yamashiki - Organ Transplantation Service, The University of Tokyo Hospital, Tokyo, Japan
Norihiro Kokudo - Division of Hepato-Biliary and Pancreatic Surgery, Department of Surgery, The University of Tokyo Hospital, Tokyo, Japan; Organ Transplantation Service, The University of Tokyo Hospital, Tokyo, Japan
Resource Type: Journal article
Publication Details: PloS one, Vol.9(3), pp.e90462-e90462
DOI: 10.1371/journal.pone.0090462
PMID: 24599320
PMCID: PMC3944011
NLM abbreviation: PLoS One
ISSN: 1932-6203
eISSN: 1932-6203
Publisher: Public Library of Science
Language: English
Date published: 2014
Academic Unit: Gastroenterology and Hepatology; Internal Medicine
Record Identifier: 9984094769102771

Metrics

12 Record Views

3 Times Cited - Web of Science